Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01406470 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Study of Immune Globulin Intravenous (Human)IVIG-SN™ in Subjects With Primary Immunodeficiency
A Phase 3 study, sponsored by Green Cross Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 45
- Enrollment target
NCT01406470 is a Phase 3 study that has completed, run by Green Cross Corporation. The registered enrollment target is 45 participants.
The verdict
NCT01406470, a Phase 3 study, has completed, sponsored by Green Cross Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 45 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics of Immune Globulin Intravenous (Human) IVIG-SN™ in subjects with primary immunodeficiency diseases.
Interventions
- DRUG Immune Globulin Intravenous (Human) 5% Liquid, IVIG-SN™
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2011-09 |
| Est. Completion | 2013-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01406470
The ClinicalTrials.gov registry entry for NCT01406470 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Green Cross Corporation, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Immune Globulin Intravenous (Human) 5% Liquid, IVIG-SN™ is the first listed.
NCT01406470 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01406470 about?
NCT01406470 is a clinical study titled "Phase 3 Study of Immune Globulin Intravenous (Human)IVIG-SN™ in Subjects With Primary Immunodeficiency". The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics of Immune Globulin Intravenous (Human) IVIG-SN™ in subjects with primary immunodeficiency diseases.
What is the current status of trial NCT01406470?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 45 participants. The study started on 2011-09. Estimated completion is 2013-07.
What interventions are being tested in trial NCT01406470?
The interventions under investigation include: Immune Globulin Intravenous (Human) 5% Liquid, IVIG-SN™ (DRUG).
Who is sponsoring clinical trial NCT01406470?
This trial is sponsored by Green Cross Corporation, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.